Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
1(50.0%)
N/A
1(50.0%)
2Total
Phase 1(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05748873Phase 1Recruiting

Promising ROd-cone DYstrophy Gene therapY

Role: lead

NCT04285398Not ApplicableActive Not Recruiting

Prospective Natural History Study of Retinitis Pigmentosa

Role: lead

NCT03975543Unknown

Retrospective Natural History Study of Retinitis Pigmentosa

Role: lead

All 3 trials loaded